The Coca-Cola Co K vs Eli Lilly And Co — how do they compare? The Coca-Cola Co K trades at $82.07 (market cap $353.32B), while Eli Lilly And Co trades at $1,163.27 (market cap $1.02T). The key difference: Eli Lilly And Co is far larger — about 2.9× The Coca-Cola Co K's market cap, and The Coca-Cola Co K pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| KO | LLY | |
|---|---|---|
Market Cap | $353.32B | $1.02T |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $1.24K |
52-Week Low | $65.67 | $625.65 |
Enterprise Value | $383.39B | $1.06T |
Dividend Yield | 2.58% | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $82.05, up 0.6% with a bearish technical signal but strong fundamentals including 27.8% net margin and consistent earnings beats. Recent quarterly EPS exceeded expectations, while analyst consensus is bullish with a $90.67 price target. The company maintains robust cash flow and a 64-year dividend growth streak, supported by stable demand trends noted by Bank of America on April 10, 2026.
Outlook remains positive due to valuation upside and dividend reliability, though technical resistance near $83 and high debt levels pose risks. Investors benefit from defensive positioning amid market volatility, but must monitor regional demand fluctuations and interest rate impacts on borrowing costs.
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →